Pulmonary CYP2A13 levels are associated with early occurrence of lung cancer-Its implication in mutagenesis of non-small cell lung carcinoma

Cancer Epidemiology

Volumn 37, Issue 5, 2013, Pages 653-659

  Chiang, Huai chih ^a,b   Lee, Huei ^b,c   Chao, How Ran ^d   Chiou, Yu Hu ^e   Tsou, Tsui Chun ^a,b  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d NATIONAL PINGTUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^e CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

CYP2A13; Early occurrence; EGFR mutations; IHC; Lung cancer; NSCLC

Indexed keywords

CYP2A13 PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

AGED; ARTICLE; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG CARCINOMA; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MUTAGENESIS; NON SMALL CELL LUNG CARCINOMA; PATIENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOKING; STAINING;

CYP2A13; EARLY OCCURRENCE; EGFR MUTATIONS; IHC; LUNG CANCER; NSCLC;

AGE FACTORS; AGED; ARYL HYDROCARBON HYDROXYLASES; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG; LUNG NEOPLASMS; MALE; MUTAGENESIS; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; SMOKING;

EID: 84884145104     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2013.04.010     Document Type: Article

References (30)

1. Su T., Bao Z., Zhang Q.Y., Smith T.J., Hong J.Y., Ding X. Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Res 2000, 60(18):5074-5079.
2. He X.Y., Shen J., Ding X., Lu A.Y., Hong J.Y. Identification of critical amino acid residues of human CYP2A13 for the metabolic activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a tobacco-specific carcinogen. Drug Metab Dispos 2004, 32(12):1516-1521.
3. Wong H.L., Murphy S.E., Hecht S.S. Cytochrome P450 2A-catalyzed metabolic activation of structurally similar carcinogenic nitrosamines: N'-nitrosonornicotine enantiomers, N-nitrosopiperidine, and N-nitrosopyrrolidine. Chem Res Toxicol 2005, 18(1):61-69.
4. He X.Y., Tang L., Wang S.L., Cai Q.S., Wang J.S., Hong J.Y. Efficient activation of aflatoxin B1 by cytochrome P450 2A13, an enzyme predominantly expressed in human respiratory tract. Int J Cancer 2006, 118(11):2665-2671.
5. Nakajima M., Itoh M., Sakai H., Fukami T., Katoh M., Yamazaki H., et al. CYP2A13 expressed in human bladder metabolically activates 4-aminobiphenyl. Int J Cancer 2006, 119(11):2520-2526.
6. Wang H., Tan W., Hao B., Miao X., Zhou G., He F., et al. Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK. Cancer Res 2003, 63(22):8057-8061.
7. Kiyohara C., Takayama K., Nakanishi Y. CYP2A13, CYP2A6, and the risk of lung adenocarcinoma in a japanese population. Journal of Health Science 2005, 51:658-666.
8. Chiang H.C., Wang C.Y., Lee H.L., Tsou T.C. Metabolic effects of CYP2A6 and CYP2A13 on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced gene mutation-a mammalian cell-based mutagenesis approach. Toxicol Appl Pharmacol 2011, 253(2):145-152.
9. Raunio H., Juvonen R., Pasanen M., Pelkonen O., Paakko P., Soini Y. Cytochrome P4502A6 (CYP2A6) expression in human hepatocellular carcinoma. Hepatology 1998, 27(2):427-432.
10. Matsuda Y., Saoo K., Yamakawa K., Yokohira M., Suzuki S., Kuno T., et al. Overexpression of CYP2A6 in human colorectal tumors. Cancer Sci 2007, 98(10):1582-1585.
11. Matsuda Y., Yamakawa K., Saoo K., Hosokawa K., Yokohira M., Kuno T., et al. CYP2A6 overexpression in human lung cancers correlates with a high malignant status. Oncol Rep 2007, 18(1):53-57.
12. Chiang H.C., Wang C.K., Tsou T.C. Differential distribution of CYP2A6 and CYP2A13 in the human respiratory tract. Respiration 2012, 84(4):319-326.
13. Toyooka S., Matsuo K., Shigematsu H., Kosaka T., Tokumo M., Yatabe Y., et al. The impact of sex and smoking status on the mutational spectrum of epidermal growth factor receptor gene in non small cell lung cancer. Clin Cancer Res 2007, 13(19):5763-5768.
14. Chien W.P., Wong R.H., Cheng Y.W., Chen C.Y., Lee H. Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors. Ann Surg Oncol 2010, 17(4):1194-1202.
15. Zhu L.R., Thomas P.E., Lu G., Reuhl K.R., Yang G.Y., Wang L.D., et al. CYP2A13 in human respiratory tissues and lung cancers: an immunohistochemical study with a new peptide-specific antibody. Drug Metab Dispos 2006, 34(10):1672-1676.
16. Fukami T., Nakajima M., Matsumoto I., Zen Y., Oda M., Yokoi T. Immunohistochemical analysis of CYP2A13 in various types of human lung cancers. Cancer Sci 2010, 101(4):1024-1028.
17. Miyazaki M., Yamazaki H., Takeuchi H., Saoo K., Yokohira M., Masumura K., et al. Mechanisms of chemopreventive effects of 8-methoxypsoralen against 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced mouse lung adenomas. Carcinogenesis 2005, 26(11):1947-1955.
18. Etzel C.J., Lu M., Merriman K., Liu M., Vaporciyan A., Spitz M.R. An epidemiologic study of early onset lung cancer. Lung Cancer 2006, 52(2):129-134.
19. Cote M.L., Wenzlaff A.S., Bock C.H., Land S.J., Santer S.K., Schwartz D.R., et al. Combinations of cytochrome P-450 genotypes and risk of early-onset lung cancer in Caucasians and African Americans: a population-based study. Lung Cancer 2007, 55(3):255-262. PMCID: 1839885.
20. Timofeeva M.N., Kropp S., Sauter W., Beckmann L., Rosenberger A., Illig T., et al. CYP450 polymorphisms as risk factors for early-onset lung cancer: gender-specific differences. Carcinogenesis 2009, 30(7):1161-1169.
21. Timofeeva M., Kropp S., Sauter W., Beckmann L., Rosenberger A., Illig T., et al. Genetic polymorphisms of MPO, GSTT1, GSTM1, GSTP1, EPHX1 and NQO1 as risk factors of early-onset lung cancer. Int J Cancer 2010, 127(7):1547-1561.
22. Rosenberger A., Illig T., Korb K., Klopp N., Zietemann V., Wolke G., et al. Do genetic factors protect for early onset lung cancer? A case control study before the age of 50 years. BMC Cancer 2008, 8:60. PMCID: 2292731.
23. Graziano C., Comin C.E., Crisci C., Novelli L., Politi L., Messerini L., et al. Functional polymorphisms of the microsomal epoxide hydrolase gene: a reappraisal on a early-onset lung cancer patients series. Lung Cancer 2009, 63(2):187-193.
24. Jalas J.R., Hecht S.S., Murphy S.E. Cytochrome P450 enzymes as catalysts of metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a tobacco specific carcinogen. Chem Res Toxicol 2005, 18(2):95-110.
25. Alexandrie A.K., Nyberg F., Warholm M., Rannug A. Influence of CYP1A1, GSTM1, GSTT1, and NQO1 genotypes and cumulative smoking dose on lung cancer risk in a Swedish population. Cancer Epidemiol Biomarkers Prev 2004, 13(6):908-914.
26. Sorensen M., Autrup H., Tjonneland A., Overvad K., Raaschou-Nielsen O. Genetic polymorphisms in CYP1B1, GSTA1, NQO1 and NAT2 and the risk of lung cancer. Cancer Lett 2005, 221(2):185-190.
27. Wassenaar C.A., Dong Q., Wei Q., Amos C.I., Spitz M.R., Tyndale R.F. Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk. J Natl Cancer Inst 2011, 103(17):1342-1346.
28. da Cunha Santos G., Shepherd F.A., Tsao M.S. EGFR mutations and lung cancer. Annu Rev Pathol 2011, 6:49-69.
29. Gandhi J., Zhang J., Xie Y., Soh J., Shigematsu H., Zhang W., et al. Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. PLoS One 2009, 4(2):e4576. PMCID: 2642732.
30. Tiano H.F., Wang R.L., Hosokawa M., Crespi C., Tindall K.R., Langenbach R. Human CYP2A6 activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK): mutational specificity in the gpt gene of AS52 cells. Carcinogenesis 1994, 15(12):2859-2866.